Novartis Immuno-oncology Drug Candidate Fails Skin Cancer Trial

ZURICH: Swiss drugmaker Novartis said on Saturday that its investigational spartalizumab immuno-oncology drug mixed with the approved medicines Tafinlar and Mekinist failed in a late-stage trial for a type of advanced skin cancer.

The drug did not improve progression-free survival in previously untreated patients with BRAF V600 mutation-positive cutaneous melanoma, compared to Tafinlar + Mekinist alone, Novartis said.

Despite the failure, Novartis is continuing development of spartalizumab, a so-called checkpoint inhibitor thought to help take the brakes off the immune system in fighting cancer, against other kind of tumors, the Basel-based company said.

Also Watch

COVID-19 Peak: Is The Worst Yet To Come? | CNN News18

Novartis has been late in developing such immuno-oncology drugs for its portfolio, a field now dominated by lucrative medicines including Merck’s Keytruda, Bristol-Myers Squibb’s Opdivo, and to a lesser extent, Roche’s Tecentriq.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Array
(
[videos] => Array
(
[0] => Array
(
[id] => 5f411b09ebd381740653d3ac
[youtube_id] => SbLbKfHLPvk
Novartis Immuno-oncology Drug Candidate Fails Skin Cancer Trial => COVID-19 Peak: Is The Worst Yet To Come? | CNN News18
)

[1] => Array
(
[id] => 5f411b85082aa874143e901b
[youtube_id] => loB6xdYkk0w
Novartis Immuno-oncology Drug Candidate Fails Skin Cancer Trial => Sushant Singh Rajput’s Autopsy Report Notes The Presence Of ‘Ligature Mark’ Around His Neck
)

)

[query] => https://pubstack.nw18.com/pubsync/v1/api/videos/recommended?source=n18english&channels=5d95e6c378c2f2492e2148a2,5d95e6c278c2f2492e214884,5d96f74de3f5f312274ca307&categories=5d95e6d7340a9e4981b2e10a&publish_min=2020-08-19T13:41:04.000Z&publish_max=2020-08-22T13:41:04.000Z&sort_by=date-relevance&order_by=0&limit=2
)

Speak Your Mind

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get in Touch

350FansLike
100FollowersFollow
281FollowersFollow
150FollowersFollow

Recommend for You

Oh hi there 👋
It’s nice to meet you.

Subscribe and receive our weekly newsletter packed with awesome articles that really matters to you!

We don’t spam! Read our privacy policy for more info.

You might also like

Conspiracy Theorists Are Coming for the 15-Minute City

Carla Francome campaigns for better cycling routes in Haringey, North London, where she moved...

Sensex soars 258 points, Nifty reclaims 11,600

New Delhi: Markets ended in green on Wednesday amid sustained foreign fund inflows with...

Eating Sharks Poses Significant Risks To Human Health Due...

Thanks to the increased demand for shark products, it has become one of Asia's...

AirAsia India: AirAsia may exit India, end joint...

MUMBAI: Malaysian carrier AirAsia said on Tuesday that it is reviewing its India operations...